Combination Therapy of IDO1 Inhibition and Anti-PD1 Mediates Anti-Tumor Immunity by Promoting Memory Immunity Development and Cytotoxicity of γδ T and NK Cells via IL-2 Signaling and by Overcoming Pro-Tumor Effects of TGF-β Signaling